GRFS

Grifols, S.A. operates as a global healthcare company specializing in the research, development, production, and commercialization of plasma-derived medicines, diagnostic systems, and hospital pharmacy products. Headquartered in Barcelona, Spain, the company was founded in 1909 and employs approximately 24,000 people worldwide. Grifols operates through three primary divisions: Biopharma, which produces essential plasma-derived therapies for treating rare and chronic diseases including immunodeficiencies, hemophilia, and alpha-1 antitrypsin deficiency; Diagnostic, which manufactures transfusion medicine solutions and clinical diagnostic products; and Bio Supplies, which provides tools and services for clinical laboratories. The company maintains one of the world's largest networks of plasma collection centers, with over 400 donation facilities primarily across the United States and Europe, processing millions of liters of plasma annually. Grifols holds a leading position in the global plasma protein therapeutics market, generating approximately €6 billion in annual revenue. Recent strategic initiatives include expansion of its plasma collection network, investments in manufacturing capacity, and development of new protein therapies. The company maintains manufacturing facilities in North America, Europe, and Asia, with significant production operations in the United States, Spain, and Ireland. Grifols trades on the Spanish stock exchanges and NASDAQ under the ticker symbol GRFS.